A frontier of research is the development of triple receptor agonists (GLP1/GIP/glucagon-RAs) that combine the efficacy of GLP1/GIP-RAs on T2D and the efficacy of GLP-1/glucagon-RAs on obesity
Today, semaglutide is also widely recognized for its effectiveness in medical weight management
Why we love it: Few peptides offer the wide range of healing benefits seen with BPC157
In simple terms: Capsules: easier, gut-focused, less direct systemic exposure Injections: more direct, stronger systemic exposure, more care required This does not mean one form is always better
Appetite & Satiety Activates GLP-1 receptors in appetite centers earlier fullness, fewer cravings, easier portion control
To continue receiving your medications, you must complete a weight and blood pressure check every month at an approved clinic